Company Overview
More
New Horizon Health Ltd is a Chinese investment holding company mainly engaged in the R & D, clinical development, test operation and commercialization of colorectal cancer, gastric cancer and cervical cancer screening products. The company sells Chang Weiqing, Pupu and other products to customers through its own network, contract sales organization (CSO) and online or electronic platforms operated by medical clinics. The company's pylorus (a fecal-based self-test for gastric cancer screening test) and Gongzenqing (a non-invasive urine cervical cancer home screening test) are under development.
CEO： Yiyou Chen
Market： Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
06606 NH HEALTH-B
17.360+0.520+3.09%
Closed 05/20 16:08 CCT
High
17.500
Open
16.900
Turnover
12.52M
Low
16.840
Pre Close
16.840
Volume
724.50K
Price Forecast
No Data
News
Comment
NH HEALTH-B: 2021 ANNUAL REPORT
NH HEALTH-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2021
NH HEALTH-B: NOTICE OF BOARD MEETING
NH HEALTH-B: POSITIVE PROFIT ALERT
NH HEALTH-B: 2021 INTERIM REPORT
NH HEALTH-B: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2021
NH HEALTH-B: NOTICE OF BOARD MEETING
NH HEALTH-B: 2020 ANNUAL REPORT
NH HEALTH-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2020
NH HEALTH-B: NOTICE OF BOARD MEETING
No More